首页|期刊导航|中国肺癌杂志|非小细胞肺癌中SRSF家族蛋白的表达和预后及功能分析

非小细胞肺癌中SRSF家族蛋白的表达和预后及功能分析OA

Expression,Prognostic and Functional Analysis of SRSF Family Proteins in Non-small Cell Lung Cancer

中文摘要英文摘要

背景与目的 非小细胞肺癌(non-small cell lung cancer,NSCLC)是全球癌症相关死亡的主要原因之一,其发生发展与复杂的分子机制密切关联.前体mRNA选择性剪接的异常在肿瘤中普遍存在,丝氨酸/精氨酸富集剪接因子(serine and arginine rich splicing factor,SRSF)家族是该过程的核心调控者.然而,目前对于SRSF家族在NSCLC中的系统性研究仍不充分.本研究旨在通过生物信息学分析与实验验证相结合的方式,系统分析SRSF家族在NSCLC中的表达谱、预后价值及其潜在生物学功能.方法 本研究整合癌症基因组图谱(The Cancer Genome Atlas,TCGA)和癌细胞系百科全书(Cancer Cell Line Encyclopedia,CCLE)等公共数据库中的转录组与临床数据,分析SRSF家族在NSCLC中的差异表达.通过Kaplan-Meier生存分析评估其表达水平与患者总生存期的关系.利用基因本体(Gene Ontology,GO)及京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)通路富集分析探讨其功能.进一步收集临床样本和细胞系,通过逆转录定量聚合酶链反应(reverse transcription quantitative polymerase chain reaction,RT-qPCR)、细胞计数试剂盒-8(cell counting kit-8,CCK-8)及细胞增殖实验验证关键成员的表达与功能.结果 SRSF家族多个成员(如SRSF1、SRSF2、SRSF3、SRSF6、SRSF7、SRSF9、SRSF10等)在NSCLC组织及细胞系中显著高表达.生存分析表明,SRSF9的高表达与患者不良预后有关,而SRSF11和SRSF12的低表达提示预后较差.功能富集分析揭示,SRSF家族不仅参与RNA剪接,还显著富集于蛋白质稳态、细胞应激反应及神经退行性疾病相关通路.体外实验证实,敲低SRSF1、SRSF2、SRSF6、SRSF9、SRSF10可显著抑制NSCLC细胞的增殖能力.结论 本研究系统描绘了SRSF家族在NSCLC中的表达与功能图谱,证实了其作为预后生物标志物和治疗靶点的潜力.本研究提示,SRSF家族可能通过破坏细胞稳态(如蛋白质稳态与应激反应)这一在肿瘤发生中至关重要的环节来驱动NSCLC的进展,为深入理解剪接失调在肺癌中的作用及开发新型治疗策略提供了理论依据.

Background and objective Non-small cell lung cancer(NSCLC)is one of the leading causes of cancer-related deaths worldwide,and its occurrence and development are closely related to complex molecular mechanisms.Alternative splicing of precursor mRNA is a key step in gene expression regulation,and its dysregulation is common in tumors.The serine/arginine-rich splicing factor(SRSF)family,a core protein family in splicing regulation,has been confirmed to play oncogenic roles in various cancers.However,systematic research on the SRSF family in NSCLC remains insufficient.This study aims to systematically analyze the specific expression patterns,clinical prognostic value,collaborative mechanisms and potential biological functions of SRSF individual members in NSCLC by the combination of bioinformatics analysis and ex-perimental verification.Methods This study integrated NSCLC transcriptome data and clinical information from public data-bases such as The Cancer Genome Atlas(TCGA)and the Cancer Cell Line Encyclopedia(CCLE),and systematically analyzed the differential expressions of SRSF family members.Kaplan-Meier survival analysis was performed to assess the correlation between the expression levels of each SRSF member and patients'overall survival(OS).Furthermore,co-expression network analysis and Gene Ontology(GO)/Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway enrichment analysis were employed to explore the biological processes and signaling pathways potentially involved by the SRSF family.Moreover,the ex-pression and function of key members were verified by reverse transcription quantitative polymerase chain reaction(RT-qPCR),cell counting kit-8(CCK-8)and cell proliferation experiments in clinical samples and cell lines.Results Multiple members of the SRSF family(e.g.,SRSF1,SRSF2,SRSF3,SRSF6,SRSF7,SRSF9,SRSF10)were found to be significantly upregulated in NSCLC tissues and cell lines.Survival analysis indicated that high expression of SRSF9 was associated with poor prognosis,while low expressions of SRSF11 and SRSF12 also indicated unfavorable outcomes.Functional enrichment analysis revealed that the SRSF family is not only involved in RNA splicing but also significantly enriched in pathways related to protein ho-meostasis,cellular stress response,and neurodegenerative diseases.In vitro experiments confirmed that knockdown of SRSF1,SRSF2,SRSF6,SRSF9 and SRSF10 significantly inhibited the proliferation of NSCLC cells.Conclusion This study systemati-cally delineates the expression and functional landscape of the SRSF family in NSCLC,confirming their potential as prognostic biomarkers and therapeutic targets.The findings suggest that the SRSF family may drive NSCLC progression by disrupting cellular homeostasis,a crucial aspect of tumorigenesis,such as protein homeostasis and stress responses.This research provides a theoretical foundation for a deeper understanding of the role of splicing dysregulation in lung cancer and for the development of novel therapeutic strategies.

涂姝祺;潘红丽;周雪霞;李雪冰;陈宇昊;张亚龙;陈嫱;范亚光;王逸璇;张洋;李思诺;陈军

300052 天津,天津医科大学总医院,天津市肺癌研究所300052 天津,天津医科大学总医院,天津市肺癌研究所300052 天津,天津医科大学总医院,天津市神经病学研究所300052 天津,天津医科大学总医院,天津市肺癌研究所300052 天津,天津医科大学总医院,天津市肺癌研究所||410013 长沙,中南大学湘雅医学院附属肿瘤医院胸外科二病区256600 滨州,滨州医学院附属医院病理科300052 天津,天津医科大学总医院,天津市肺癌研究所||300202 天津,天津市胸科医院呼吸与危重症医学科300052 天津,天津医科大学总医院,天津市肺癌研究所300052 天津,天津医科大学总医院,天津市肺癌研究所||300052 天津,天津医科大学总医院,天津市神经病学研究所300052 天津,天津医科大学总医院,天津市肺癌研究所300052 天津,天津医科大学总医院,天津市肺癌研究所300052 天津,天津医科大学总医院,天津市肺癌研究所

肺肿瘤SRSF家族生存预后选择性剪接生物信息学分析细胞增殖与活力

Lung neoplasmsSRSF familySurvival prognosisAlternative splicingBioinformatics analysisCell proliferation and viability

《中国肺癌杂志》 2026 (1)

15-25,11

本研究受国家自然科学基金项目(No.82273019,No.82472643)、天津医科大学总医院优秀青年基金项目(No.22ZYYYQ01)、天津市科技重大专项与工程公共卫生科技重大专项重点项目(No.24ZXGZSY00040)、天津市卫生健康科技基金项目(No.TJWJ2023QN063)和天津市医学重点学科建设项目(No.TJYXZDXK-3-002B,No.TJYXZDXK-3-006A-2)资助 This study was supported by the grants from National Natural Science Foundation of China(No.82273019,to Xue-bing LINo.82472643,to Xuexia ZHOU),the Outstanding Youth Foundation of Tianjin Medical University General Hospital(No.22ZYYYQ01,to Xuexia ZHOU),Tianjin Science and Technology Major Special Project and Engineering-public Health Science and Technology Major Special Project Key Project(No.24ZXGZSY00040,to Yaguang FAN),the Tianjin Health Sci-ence and Technology Project(No.TJWJ2023QN063,to Qiang CHEN)and the Tianjin Key Medical Discipline Construction Project(No.TJYXZDXK-3-002B,to Jun CHENNo.TJYXZDXK-3-006A-2,to Jun CHEN).

10.3779/j.issn.1009-3419.2026.106.02

评论